NewGen has a strong management team with the skill set, record of accomplishment and experience to be successful and maximize share-holder returns. The aggregate industry experience of the management team and Board of Directors is 100+ years.
Dr. Navdeep Jaikaria – Founder, Chairman & CEO: Formerly, a Managing Director & Head of Equity Research (Rodman & Renshaw – a leading healthcare investment bank headquartered in New York) and a ranked Senior Biotechnology Equity Research analyst (Ranked top-five in the Wall Street Journal’s 2007 “Best on the Street Survey”; top three by Starmine in 2006 based on portfolio performance) on Wall Street for several years.
Possesses deep industry and scientific knowledge and a well-proven ability to identify significant and undervalued biopharmaceutical assets. Has served as a consultant and advisor to senior managements of biotech & pharmaceutical companies. Navdeep’s industry perspectives have been widely cited in both print and broadcast media including The Wall Street Journal, Financial times, BusinessWeek, Forbes, CNNfn, CNBC and CNN India. He ran a non-for-profit group in India from 1992 to 1994 and currently sits on company (both public and private) as well as not-for-profit Boards.
Dr. Jaikaria was a National Talent Scholar in India and holds a B.Sc. (Hons) in Human Biology from the All India Institute of Medical Sciences, New Delhi; Ph.D. from New York Medical College and was a Post-Doctoral Fellow at The Rockefeller University, New York.
Dr. Abu Alam - Senior VP R&D and Regulatory Affairs: An accomplished pharmaceutical senior executive for over 38 years, Dr. Alam most recently served as the Senior Vice President of New Business Development, Akorn and in that capacity led Akorn's Product and Business Development programs. He has spent his entire career specializing in the research and development of branded/generic pharmaceuticals in both the prescription and over-the-counter markets.
Prior to Akorn, Inc., Dr. Alam held numerous senior management roles in the pharmaceutical industry with organizations such as: EJ Financial, Lyphomed, Fujisawa, American Critical Care, Adria Laboratories, and Rohm & Haas. Dr. Alam also served as a management consultant to NeoPharm, Carbomed, Tech-India and Unimed in the pharmaceutical industry. Dr. Alam's impressive credentials include 22 deals, 4 in-licensing, ~175 product launches in the US, 3 orphan NDA's, one 505 B2 NDA, 2 patent IV challenges, 27 published papers; 14 U.S. patents; and an adjunct professorship at the University of Illinois.
Sanjeev Srivastava – Chief Financial and Business Development Officer: Sanjeev has over 15 years of cross border experience in corporate finance and executive leadership; 9+ years of working at JP Morgan investment bank and 7+ years of working as the CFO for several small to mid size companies from healthcare, technology to retail. He served as the CFO for a not for profit in US and India that ran a healthcare NGO in India.
Academic background includes a BS in Chemical Engineering from University of Rochester and a MBA in Finance & Marketing from New York University - Stern School of Business.